SUBSCRIBE
SUBSCRIBE

Biogen

NEWS
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Deals
Who Can Gobble Up Biogen, or Who Can Biogen Buy
November 16, 2015
 · 
4 min read
Drug Development
After Dropping the “Biogen Bombshell,” CEO Turns R&D Focus to Neurological Diseases Like Alzheimer’s
November 12, 2015
 · 
3 min read
Job Trends
As Biogen Cuts 11% of Staff, Company Doubles Down on Clinical Trials
November 5, 2015
 · 
3 min read
Business
In Face of Dropping Stocks and Failed Phase III, Biogen Restructures, Slashes Programs and Lays off 880 People
October 21, 2015
 · 
3 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Job Trends
Analysts Try to Pry Open Biogen as Stock Continues Slump and Investors Jump Ship
October 15, 2015
 · 
3 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Business
Biogen Wants to Go Beyond Drugs, Eyes Medtech
September 23, 2015
 · 
4 min read
Genetown
Celgene, Amgen, Biogen: Why Big-Cap Biotech Short Interest Is Up
September 14, 2015
 · 
1 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
Biogen Forges $544M Deal to Take on Celgene With a Rival Autoimmune Drug
September 9, 2015
 · 
3 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
Applied Genetic Surges on $1 Billion+ Eye Deal With Biogen
August 20, 2015
 · 
2 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2023 Best Places to Work
JOBS
IN THE PRESS
Press Releases
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
December 23, 2025
 · 
13 min read
Press Releases
Canadian HTA Assessments Recognize Therapeutic Value of QALSODY™ (tofersen injection) and its Potential to Modify Disease Progression in Individuals Living with SOD1-ALS
December 11, 2025
 · 
6 min read
Press Releases
Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada
December 10, 2025
 · 
8 min read
Press Releases
“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List
December 9, 2025
 · 
11 min read
Press Releases
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
December 8, 2025
 · 
19 min read
Press Releases
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
December 8, 2025
 · 
19 min read
Press Releases
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025
December 4, 2025
 · 
24 min read
Press Releases
New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
December 3, 2025
 · 
21 min read
Press Releases
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
December 2, 2025
 · 
16 min read
Press Releases
Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
December 2, 2025
 · 
16 min read
Load More